Bacterial DNA and associated macromolecular synthesis machinery

Bacterial DNA and the associated macromolecular synthesis machinery serve as the primary therapeutic target for nitroimidazole and nitrofuran classes of antibiotics in anaerobic and microaerophilic organisms. In these specific environments, the drugs act as prodrugs that undergo reductive activation by low-potential electron transport proteins, such as ferredoxin or flavodoxin [1, 2]. The resulting highly reactive nitroso and radical intermediates cause extensive damage to the bacterial genome through covalent binding and oxidative stress [2, 4]. This damage leads to immediate DNA strand breakage and the subsequent inhibition of critical macromolecular processes, including replication, transcription, and translation [2, 3]. This multi-targeted approach is particularly effective against anaerobic bacteria and certain protozoa because the activation process is strictly dependent on their unique anaerobic metabolic pathways [1, 4]. Consequently, the disruption of these essential cellular functions results in rapid bactericidal activity and cell death [2]. Resistance can occur through the downregulation of activating enzymes or mutations in the DNA repair machinery of the target organism [4].

Other names

Bacterial DNABacterial genomeNucleic acid synthesis machineryBacterial macromolecular synthesis complex

The target is disrupted via the reductive activation of nitro-group-containing prodrugs by anaerobic metabolic enzymes (such as ferredoxin or flavodoxin), which generates short-lived, highly reactive radicals that induce DNA strand breakage and inhibit the synthesis of DNA, RNA, and proteins [1, 2, 4].